新一代人工智能技术驱动下的新药研发  

Research and development of new drugs driven by novel generation AI technology

作　　者：吴昊 林铭 孙懿[1] 赵欣[1] 蒲小平[1] WU Hao;LIN Ming;SUN Yi;ZHAO Xin;PU Xiao-ping(Dept of Molecular and Cellular Pharmacology, School of Pharmaceutical Science, Peking University, Beijing 100191,China)

机构地区：[1]北京大学药学院分子与细胞药理学系

出　　处：《中国药理学通报》2019年第7期889-893,共5页Chinese Pharmacological Bulletin

基　　金：“十三五”国家科技重大新药创制项目(No 2017ZX09101003-009-006);国家自然科学基金资助项目(No U1603128)

摘　　要：传统新药研发风险高而且周期长,资金投入也逐年增长,而人工智能(artificial intelligence,AI)技术可以改变传统新药研发模式,提高研发效率并降低再研成本。AI技术不仅能应用于靶点筛选,还能应用于表型筛选(phenotypic screening),从而开展针对复杂疾病的新药研发,同时,小样本学习使得AI技术更加具有普适性。而AlphaGo Zero的出现为AI技术带来重大突破,将会推动新药研发的快速发展。Traditional new drug research and development is of high risk and long-term, with increasing investment year by year, which can be altered by AItechnology to improve the efficiency of R&D and decrease the cost of re-research. AI technology can be applied not only to target screening, but also to phenotypic screening to develop new drugs for complex diseases. At the same time, one-shot learning makes AI technology more comprehensive. The emergence of AlphaGo Zero has brought about a major breakthrough in AI technology, which will promote the rapid development of new drug R&D.

关 键 词：新药研发 人工智能技术 靶点筛选 表型筛选 小样本学习 AlphaGo ZERO 

分 类 号：R-05[医药卫生] R319